Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy
McCulloch, Rory Visco, Carlo Eyre, Toby Phillips, Neil Tucker, David Quaglia, Francesca McMillan, Annabel Lambert, Jonathan Crosbie, Nicola
McCulloch, Rory
Visco, Carlo
Eyre, Toby
Phillips, Neil
Tucker, David
Quaglia, Francesca
McMillan, Annabel
Lambert, Jonathan
Crosbie, Nicola
Glos Author
Date
2020-05
Journal Title
Subject
Type
Journal Article
Collections
Abstract
Patients with mantle cell lymphoma progressing on Bruton's tyrosine kinase inhibitor (BTKi) have very poor prognosis and there is currently no standard of care. In this retrospective cohort study, patients progressing on BTKi received R-BAC (rituximab, bendamustine, cytarabine). Overall response rate was 83% (complete response 60%) and 31% were bridged to allogeneic stem cell transplant (alloSCT). Median progression-free survival was 10.1 months (95% confidence interval (CI) 6·9-13·3) and median overall survival was 12·5 months (95% CI 11·0-14·0). In those consolidated with alloSCT only one patient relapsed. R-BAC demonstrates a high response rate in the post-BTKi setting and in transplant eligible patients is an effective bridge to alloSCT.
Citation
McCulloch, R., Visco, C., Eyre, T. A., Frewin, R., Phillips, N., Tucker, D. L., Quaglia, F. M., McMillan, A., Lambert, J., Crosbie, N., & Rule, S. (2020). Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. British journal of haematology, 189(4), 684–688. https://doi.org/10.1111/bjh.16416